Zoetis Inc. Class A (ZTS) Covered Calls

Zoetis Inc. is the worlds largest animal health company, specializing in the discovery, development, and manufacture of medicines, vaccines, and diagnostic products for livestock and companion animals. A member of the S&P 500, Zoetis operates in over 100 countries. The company serves veterinarians, livestock producers, and pet owners, leveraging a diverse portfolio across eight species and seven major product categories including parasiticides, dermatology, and monoclonal antibodies.

You can sell covered calls on Zoetis Inc. Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ZTS (prices last updated Wed 10:30 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Zoetis Inc. (ZTS) is the global leader in the animal health industry, a sector characterized by high barriers to entry and steady, non-cyclical demand. The company’s business model is balanced between Companion Animal (pets) and Livestock segments. Zoetis captures significant value through a "Continuum of Care" strategy that integrates diagnostics with therapeutic treatments. Revenue is increasingly driven by "blockbuster" franchises in dermatology, such as Apoquel and Cytopoint, and parasiticides like Simparica Trio.

By early 2026, Zoetis has pivoted toward long-term chronic care solutions. A major milestone in February 2026 was the release of a comprehensive three-year global safety study for Librela, which successfully stabilized clinician confidence following 2024-2025 regulatory scrutiny. For FY2026, management is targeting organic operational revenue growth of 3% to 5%, supported by a $1 billion investment in manufacturing and R&D. The company recently increased its quarterly dividend by 6% to $0.53 per share, continuing its record of returning capital to shareholders while maintaining a fortress balance sheet with a return on equity exceeding 60%.

Competitive Landscape

The competitive landscape for Zoetis consists of specialized animal health firms and the animal health divisions of large pharmaceutical conglomerates. Primary rivals that are publicly traded on the NYSE or NASDAQ and offer active options markets include IDEXX Laboratories, Inc. and Elanco Animal Health Incorporated. IDEXX is the leader in pet diagnostics, while Elanco competes directly in the parasiticide and livestock markets.

Other notable competitors in the veterinary and specialty pharma sectors with active options trading include Pfizer Inc. and Merck & Co., Inc.. Zoetis distinguishes itself through its pure-play animal health focus; unlike its human-pharma peers, Zoetis is not burdened by patent cliffs or the "Inflation Reduction Act" pricing pressures. This independence, combined with its 2,000+ regulatory approvals over the last decade and a unique direct-to-veterinarian sales force, creates a wide economic moat that allows the company to maintain premium margins and high customer loyalty in both suburban clinics and global farm operations.

Strategic Outlook

Strategic innovation is currently focused on Next-Generation Specialty Areas, specifically chronic kidney disease, cardiology, and oncology. The company is prioritizing its "Digital & Data" segment, utilizing AI-driven diagnostics to predict illness before clinical signs appear. These efforts are designed to expand the total addressable market by approximately $7 billion by 2030, ensuring that Zoetis remains at the forefront of the "humanization of pets" trend.

The long-term outlook involves a commitment to Sustainability and Supply Chain Resilience, with a focus on expanding its international presence in high-growth markets like Brazil and China. Management is prioritizing a disciplined capital allocation strategy that balances internal innovation with opportunistic acquisitions in the genetics and tech-enabled care space. By leveraging its unparalleled R&D engine and market-leading scale, Zoetis Inc. aims to remain the definitive institutional standard for the animal health asset class.

Want more examples? ZTO Covered Calls | ZUMZ Covered Calls